A carregar...
Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives
Glioblastomas are aggressive, fast-growing primary brain tumors. After standard-of-care treatment with radiation in combination with temozolomide, the overall prognosis of newly diagnosed patients remains poor, with a 2-year survival rate of less than 20%. The remarkable survival benefit gained with...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7140029/ https://ncbi.nlm.nih.gov/pubmed/32235752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12030751 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|